Table 3.
National Animal Supplement Council (NASC) Ingredient Risk Report for hemp and hemp-derived compounds in dogs as of November 20, 2023.
| Year | Adverse events (report rate/million administrations sold) | Serious adverse events (report rate/million administrations sold) | Administrations solda |
|---|---|---|---|
| 2010 | 0.00 | 0.00 | 25,016 |
| 2011 | 0.00 | 0.00 | 29,098 |
| 2012 | 0.00 | 0.00 | 104,421 |
| 2013 | 11.74 | 0.00 | 255,642 |
| 2014 | 0.00 | 0.00 | 543,023 |
| 2015 | 0.00 | 0.00 | 894,762 |
| 2016 | 0.00 | 0.00 | 1,755,993 |
| 2017 | 0.12 | 0.00 | 8,124,015 |
| 2018 | 0.50 | 0.00 | 40,395,501 |
| 2019 | 0.87 | 0.00 | 115,607,342 |
| 2020 | 2.26 | 0.00 | 190,065,703 |
| 2021 | 2.09 | 0.02 | 293,080,512 |
| 2022 | 2.24 | 0.03 | 274,129,622 |
| 2023b | 3.16 | 0.02 | 152,536,208 |
| Grand Total | 2.19 | 0.01 | 1,077,546,857 |
Events are divided into adverse events and serious adverse events and reported based on the number of administrations in each container sold.
a Number of administrations sold is assumed to be a close approximation to administrations consumed.
b Usage data for 2023 is incomplete.